Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Invested Capital: 2020

Historic Return on Invested Capital for Coherus Oncology (CHRS) over the last 1 years, with Dec 2020 value amounting to 0.40%.

  • Coherus Oncology's Return on Invested Capital was N/A to 0.40% in Q4 2020 from the same period last year, while for Dec 2020 it was 0.40%, marking a year-over-year change of. This contributed to the annual value of 1.24% for FY2023, which is N/A change from last year.
  • Latest data reveals that Coherus Oncology reported Return on Invested Capital of 0.40% as of Q4 2020, which was down 48.23% from 0.77% recorded in Q3 2020.
  • In the past 5 years, Coherus Oncology's Return on Invested Capital ranged from a high of 1.07% in Q2 2020 and a low of 0.40% during Q4 2020.
  • For the 1-year period, Coherus Oncology's Return on Invested Capital averaged around 0.80%, with its median value being 0.86% (2020).